Hantash joins PharmaNet/i3

Friday, October 12, 2012 02:06 PM

PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Jamil Hantash, MSc, M.B.A., as director of Immunochemistry Operations at PharmaNet/i3’s Princeton, N.J., bioanalytical laboratory. 

Hantash brings a wealth of operational and scientific experience in large molecule bioanalysis. For the last 12 years he served in senior laboratory management positions at other CROs. At PharmaNet/i3, Hantash will manage laboratory operations related to macromolecule analysis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs